Molecular Signatures in Inflammatory Skin Disease

Summary

This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. To this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. The different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling iPOP) for generating insights into disease pathways and for extraction of molecular signatures that correspond to clinical severity scores. It will provide a good starting point for planning future trials aimed at identifying biological patterns useful for guiding targeted treatment.

Conditions

• Atopic Dermatitis
• Psoriasis

Interventions

DRUG

Anti-TNF

Subject receives anti-TNF antibodies open-label as per guidelines

DRUG

Anti-IL12/23

Subject receives anti-IL12/23 antibodies open-label as per guidelines

DRUG

Anti-IL17

Subject receives anti-IL17 antibodies open-label as per guidelines

DRUG

Dupilumab

Subject receives Dupilumab open-label as per guidelines

DRUG

Anti-IL23

Subject receives anti-IL23 antibodies open-label as per guidelines

DRUG

Baricitinib

Subject receives Baricitinib open-label as per guidelines

DRUG

Abrocitinib

Subject receives Abrocitinib open-label as per guidelines

DRUG

Upadacitinib

Subject receives Upadacitinib open-label as per guidelines

DRUG

Tralokinumab

Subject receives Tralokinumab open-label as per guidelines

DRUG

Lebrikizumab

Subject receives Lebrikizumab open-label as per guidelines

DRUG

Nemolizumab

Subject receives Nemolizumab open-label as per guidelines

Sponsors & Collaborators

• Prof. Dr. Stephan Weidinger

  lead OTHER

Principal Investigators

• Stephan Weidinger, MD · Department of Dermatology, university Hospital Schleswig-Holstein, Campus Kiel

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-01-20

Primary Completion

2028-12-31

Completion

2029-12-31

FDA Drug

Yes

Countries

• Germany

Study Locations